Target Name: HAP1
NCBI ID: G9001
Review Report on HAP1 Target / Biomarker Content of Review Report on HAP1 Target / Biomarker
HAP1
Other Name(s): Huntingtin-associated protein 1 | epididymis secretory sperm binding protein | HAP1_HUMAN | HAP1 variant 1 | neuroan 1 | Huntingtin-associated protein 1 (isoform 1) | Huntingtin-associated protein 2 | HAP-1 | huntingtin-associated protein 2 | Huntingtin associated protein 1, transcript variant 2 | Huntingtin-associated protein 1 (neuroan 1), transcript variant 1 | Huntingtin-associated protein 1 (isoform 2) | huntingtin associated protein 1 | Neuroan 1 | HLP | HAP1 variant 2 | HAP2 | HIP5 | hHLP1

HAP1: A Protein Involved in Many Cellular Processes

HAP1 (Huntingtin-associated protein 1) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the huntingtin family of proteins, which are known for their ability to interact with dystrophin, a protein that is involved in many cellular processes throughout the body.

One of the functions of HAP1 is to regulate the activity of huntingtin proteins, which are known for their ability to interact with a variety of proteins and to play a role in a variety of cellular processes, including cell signaling, protein synthesis, and stress response.

HAP1 has also been shown to play a role in the regulation of cellular processes that are related to the development and maintenance of the nervous system. For example, studies have shown that HAP1 is involved in the regulation of the growth and differentiation of neural stem cells, and that it plays a role in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In addition to its role in cellular processes, HAP1 has also been shown to be involved in the regulation of the immune system. Studies have shown that HAP1 is involved in the regulation of the production and function of immune cells, and that it plays a role in the development of autoimmune diseases.

Given the variety of functions that HAP1 has been shown to play, it is a promising target for drug development. Researchers are currently working to develop compounds that can inhibit the activity of HAP1 and to use these compounds as a treatment for a variety of diseases.

One of the challenges in the development of drugs that target HAP1 is the fact that it is a protein that is expressed in a wide variety of tissues and cells throughout the body, and that it is involved in a variety of cellular processes. This makes it difficult to predict exactly how a drug will affect HAP1 activity and to develop effective treatments.

In addition to its challenges, HAP1 is also a protein that is involved in the regulation of many cellular processes, and that the effects of a drug on HAP1 activity may be difficult to predict. This makes it difficult to develop effective treatments for diseases that are caused by changes in HAP1 activity.

Overall, HAP1 is a protein that is involved in a variety of cellular processes throughout the body, and that has been shown to play a role in the regulation of many important cellular processes. As a result, it is a promising target for drug development and could be used to treat a variety of diseases.

Protein Name: Huntingtin Associated Protein 1

Functions: Originally identified as neuronal protein that specifically associates with HTT/huntingtin and the binding is enhanced by an expanded polyglutamine repeat within HTT possibly affecting HAP1 interaction properties. Both HTT and HAP1 are involved in intracellular trafficking and HAP1 is proposed to link HTT to motor proteins and/or transport cargos. Seems to play a role in vesicular transport within neurons and axons such as from early endosomes to late endocytic compartments and to promote neurite outgrowth. The vesicular transport function via association with microtubule-dependent transporters can be attenuated by association with mutant HTT. Involved in the axonal transport of BDNF and its activity-dependent secretion; the function seems to involve HTT, DCTN1 and a complex with SORT1. Involved in APP trafficking and seems to facilitate APP anterograde transport and membrane insertion thereby possibly reducing processing into amyloid beta. Involved in delivery of gamma-aminobutyric acid (GABA(A)) receptors to synapses; the function is dependent on kinesin motor protein KIF5 and is disrupted by HTT with expanded polyglutamine repeat. Involved in regulation of autophagosome motility by promoting efficient retrograde axonal transport. Seems to be involved in regulation of membrane receptor recycling and degradation, and respective signal transduction, including GABA(A) receptors, tyrosine kinase receptors, EGFR, IP3 receptor and androgen receptor. Among others suggested to be involved in control of feeding behavior (involving hypothalamic GABA(A) receptors), cerebellar and brainstem development (involving AHI1 and NTRK1/TrkA), postnatal neurogenesis (involving hypothalamic NTRK2/TrkB), and ITPR1/InsP3R1-mediated Ca(2+) release (involving HTT and possibly the effect of mutant HTT). Via association with DCTN1/dynactin p150-glued and HTT/huntingtin involved in cytoplasmic retention of REST in neurons. May be involved in ciliogenesis. Involved in regulation of exocytosis. Seems to be involved in formation of cytoplasmic inclusion bodies (STBs). In case of anomalous expression of TBP, can sequester a subset of TBP into STBs; sequestration is enhanced by an expanded polyglutamine repeat within TBP. HAP1-containing STBs have been proposed to play a protective role against neurodegeneration in Huntigton disease (HD) and spinocerebellar ataxia 17 (SCA17)

The "HAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

HAPLN1 | HAPLN2 | HAPLN3 | HAPLN4 | HAPSTR1 | HAR1A | HAR1B | HARBI1 | HARS1 | HARS2 | HAS1 | HAS2 | HAS2-AS1 | HAS3 | HASPIN | HAT1 | HAUS1 | HAUS1P1 | HAUS2 | HAUS3 | HAUS4 | HAUS5 | HAUS6 | HAUS7 | HAUS8 | HAVCR1 | HAVCR1P1 | HAVCR2 | HAX1 | HAX1P1 | HBA1 | HBA2 | HBAP1 | HBB | HBBP1 | HBD | HBE1 | HBEGF | HBG1 | HBG2 | HBM | HBO1 complex | HBP1 | HBQ1 | HBS1L | HBZ | HBZP1 | HCAR1 | HCAR2 | HCAR3 | HCCAT5 | HCCS | HCFC1 | HCFC1R1 | HCFC2 | HCG11 | HCG14 | HCG15 | HCG17 | HCG18 | HCG20 | HCG21 | HCG22 | HCG23 | HCG25 | HCG26 | HCG27 | HCG4 | HCG4B | HCG4P11 | HCG4P3 | HCG4P5 | HCG4P8 | HCG9 | HCGVIII-2 | HCK | HCLS1 | HCN1 | HCN2 | HCN3 | HCN4 | HCP5 | HCRT | HCRTR1 | HCRTR2 | HCST | HDAC1 | HDAC10 | HDAC11 | HDAC11-AS1 | HDAC1P1 | HDAC2 | HDAC2-AS2 | HDAC3 | HDAC4 | HDAC4-AS1 | HDAC5 | HDAC6 | HDAC7 | HDAC8